Menu
NEUROINNOVATECH is a development company with an ambition to develop the preferred innovative treatment of CNS disorders. Upon successfully demonstrating the project’s feasibility in treating CNS disorders and securing worldwide IP rights, NEUROINNOVATECH will proceed with its projected sale of the projects. The anticipated timeline for advancing the development projects for the and establish the global IP rights is approx. 30 months, starting in September 2024.
The governance policies at NEUROINNOVATECH provides the company with a comprehensive structure ensuring practices to meet all legal and regulatory requirements. We further strive to implement good corporate governance to all stakeholders. Operations within NEUROINNOVATECH are conducted with utmost financial integrity, all decisions are taken in the best interests of the shareholders both for the minority and majority shareholders. Questions etc. can be assessed through our email info@neuroinnovatech.com
The first financial year ends 31. March 2025.